UCLA researchers to present on latest advancements in cancer therapies at annual ASCO meeting
Physicians and scientists from UCLA’s Jonsson Comprehensive Cancer Center will be joining the world's leading scientists, clinicians, advocates and industry luminaries from institutions around the world to discuss the most recent advancements in cancer research at the American Society of Clinical Oncology (ASCO) annual meeting.
The ASCO Annual Meeting offers education and scientific sessions in all aspects of oncology, and this year’s theme is “Caring for every patient, learning from every patient.” Due to the COVID-19 pandemic, the event will be held virtually from May 29 to June 3. Presentations from UCLA researchers will highlight the latest developments in the basic, translational, clinical, and prevention-focused research, emphasizing work in immunotherapy and combination therapies.
More than a dozen abstracts, sessions and symposia at ASCO 2020 will feature members of the Cancer Center. Below are UCLA-led oral and poster presentations where UCLA researchers are speaking or appearing.
For the complete list of ASCO 2020 abstracts, please visit their website.
First author: Jonathan Goldman
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
First author: Benjamin Ellingson
Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group.
First author: Zev Wainberg
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
First author: Bartosz Chmielowski
A phase Ia/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.
First author: Aaron Elliott Lisberg
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).
First author: J. Randolph Hecht
Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).
First author: Edward Garon
CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
First author: Richard Finn
A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
First author: Richard Finn
Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
First author: Jeremie Calais
Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
First author: Nicholas Bernthal
Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.
First author: Sara Hurvitz
Oncology team perception and patient experience discordances in triple-negative breast cancer (TNBC) care.